Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 8

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 8
---
. We have been honored to receive some of our industry’s most prestigious ratings and recognitions. To date, we have received more than 40 Great Place to Work and Top Employer rankings globally.

| ​​​​​​​                                                                                                               | ​ | ​ |   |                                                                   | ​ | ​ |
| Workplace                                                                                                             |   |   |   | Environmental, Social                                             
 and Governance                                                    |   |   |
| ✓–Included for nine consecutive years✓®–Included for five consecutive years✓Scored 100% for seven consecutive years✓​ |   |   | ​ | ✓✓✓✓✓​                                                            |   |   |
| ✓Great Place to Work’s World’s Best Workplaces™–Included since 2017                                                   
 ✓Seramount “100 Best Companies” –Included since 2014                                                                  
 ✓FORTUNE 100 Best Companies to Work For®–Included since 2018                                                          
 ✓Human Rights Campaign Corporate Equality Index –Scored 100% since 2016                                               
 ✓Disability:IN Best Places to Work for Disability Inclusion –Scored 100% since 2021                                   |   |   | ​ | ✓Dow Jones Sustainability World and North America Indices         
 ✓EcoVadis Corporate Social Responsibility Assessment Silver Medal 
 ✓FTSE4Good Index                                                  
 ✓Energy Star Partner of the Year                                  
 ✓UN Global Compact member                                         |   |   |

For more information, visit https://news.abbvie.com/AbbVie-ratings-and-recognition-fact-sheet

10 | 2025 Proxy Statement

| ​ | ​             |
| ​ | PROXY SUMMARY |

Executive Compensation Highlights

| ​                                                                                                                                                                                                       |
| The compensation committee has designed and implemented an executive compensation program in which a substantial majority of named executive officer (NEO) compensation at AbbVie is performance-based. |

The goals of our compensation program are to:

|   |                                                                                         | ​ |   |                                                                                                            | ​ |   |                                                                                                                             |
| 1 | Align executive interests with the drivers of stockholder returns and profitable growth | ​ | 2 | Support achievement of the company’s primary business goals to have a remarkable impact on patients’ lives | ​ | 3 | Attract and retain world-class executives whose talents and contributions sustain the growth in long-term stockholder value |

When determining NEO compensation, the committee first considers the median of the competitive marketplace (as derived primarily from the Health Care Peer Group approved by the committee